Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of 1 of the following:

  * Metastatic or unresectable malignancy for which standard curative or palliative measures do not exist or are no longer effective (phase I) (phase I study closed to accrual as of 8/23/04)
  * Melanoma (phase I and II)
* Measurable disease (phase II)
* No history or clinical evidence of CNS disease, including primary brain tumor or brain metastases
* Performance status - ECOG 0-1
* More than 3 months
* WBC at least 3,000/mm\^3
* Absolute granulocyte count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* No history of bleeding diathesis or coagulopathy
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* AST and ALT no greater than 2.5 times ULN
* INR no greater than 1.5
* APTT normal
* Creatinine no greater than 2.0 times ULN
* Creatinine clearance at least 40 mL/min
* No proteinuria
* Urinary protein less than 500 mg/24 hours
* No history of stroke
* No uncontrolled hypertension within the past 6 months

  * Blood pressure less than 150/100 mm Hg on a stable antihypertensive regimen
* None of the following within the past 6 months:

  * Myocardial infarction
  * Unstable angina
  * New York Heart Association class II-IV congestive heart failure
  * Serious cardiac arrhythmia requiring medication
  * Grade II or greater peripheral vascular disease
  * Transient ischemic attack
  * Cerebrovascular accident
  * Other arterial thromboembolic event
  * Other clinically significant cardiovascular disease
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for at least 3 months after study participation
* No seizures not controlled with standard medical therapy
* No prior allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biological composition to imatinib mesylate
* No serious, nonhealing wound, ulcer, or bone fracture
* No ongoing or active infection requiring parenteral antibiotics
* No significant traumatic injury within the past 28 days
* No psychiatric illness or social situation that would preclude study compliance
* No other concurrent uncontrolled illness
* More than 4 weeks since prior immunotherapy
* More than 8 weeks since prior monoclonal antibody therapy
* No concurrent prophylactic granulocyte or platelet colony-stimulating factors
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* No more than 1 prior cytotoxic chemotherapy regimen for advanced disease (phase II)
* More than 4 weeks since prior radiotherapy
* More than 28 days since prior major surgical procedure or open biopsy
* Recovered from prior therapy
* No concurrent chronic daily aspirin (greater than 325 mg/day) or nonsteroidal anti-inflammatory drugs known to inhibit platelet function
* No recent or concurrent full-dose anticoagulants (except as required to maintain patency of preexisting permanent indwelling IV catheters) or thrombolytic agent
* No concurrent grapefruit juice
* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational or commercial agents or therapies directed at the malignancy
* No other concurrent investigational agents